A long-lasting universal flu vaccine
For decades, researchers have been doggedly pursuing a universal flu vaccine--one that would protect against the evolving influenza virus for years rather than just a single season--with little success. The bug mutates so quickly that a new vaccine must be specially formulated each year. But a relatively new strategy, targeting a rarely seen portion of the virus, is now showing some success.
A novel vaccine developed by microbiologist Peter Palese and collaborators at Mount Sinai School of Medicine in New York showed protective effects in rodents against three different flu strains, with protection ranging from mild (against hemagglutinin 1, such as that of the H1N1 or "swine" flu) to middling (against the avian flu H5 subtype) to absolute (against the common H3 flu subtype). While the results are far from perfect, the proof-of-principle demonstrates the potential for a universal flu vaccine.
- Reform Puts Vise Grips on Physicians
- Look Beyond Nurse-Patient Ratios
- Medicare Opt-Out a Viable Physician Strategy
- NPP Demand Rising Under Value-Based Care Models
- How Physicians Can Help Ease Mental Health Provider Shortages
- Boston Marathon Bombing Yields Lessons for Hospitals
- Providers Lag as Consumers Set Agenda
- Esther Dyson Launches Population Health Challenge
- Physicians as Economic Powerhouses and Tech Laggards
- Hospital Groups Back NQF Report on Patient Sociodemographics